$CRY (CryoLife Inc.)

$CRY {{ '2016-04-14T15:34:51+0000' | timeago}} • Announcement

$CRY said Genesee has agreed to continue to supply PhotoFix to $CRY until it establishes manufacturing capabilities at its headquarters in suburban Atlanta, GA. $CRY anticipates it will be manufacturing PhotoFix by mid 2017.

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$CRL {{ '2018-01-16T14:14:39+0000' | timeago}} • Announcement

$CRL appointed Jean-Paul Mangeolle, former President of AB SCIEX, to its BoD. As a member of the Board, he will serve on the Audit and Compensation Committees.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$CRL {{ '2018-01-11T13:12:01+0000' | timeago}} • Announcement

Drug research solutions provider $CRL has acquired KWS BioTest, a contract research organization, for about $20MM. The deal also includes a potential additional payment of up to $4MM based on future performance. The acquisition is not expected to be material to Charles River’s GAAP or non-GAAP results from operations this year.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$BSX {{ '2018-01-09T20:36:17+0000' | timeago}} • Announcement

Healthcare solutions firm $BSX said its 4Q17 sales is estimated to have grown about 8% YoY, on a reported basis, to $2.41Bil. In the whole of fiscal 2017, sales advanced 8% annually to $9.05Bil. The growth reflects strong sales performance by all product groups.

$CUTR {{ '2018-01-08T18:33:07+0000' | timeago}} • Announcement

$CUTR introduced Juliet and Secret RF to its product offerings of laser and energy-based devices. The Juliet laser is intended for treatment in the area of women’s health. Secret RF is a new fractional radio frequency microneedling device that effectively remodels collagen, improves mild wrinkles, and diminishes scars.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$BAX {{ '2018-01-08T14:03:11+0000' | timeago}} • Announcement

$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$BDX {{ '2017-12-29T16:54:30+0000' | timeago}} • Announcement

$BDX acquired $BCR. Beginning with 2Q18, $BDX will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment.

$BDX {{ '2017-12-29T16:54:14+0000' | timeago}} • Announcement

$BDX has acquired $BCR. $BDX does not expect the acquisition to have a material impact on its financial results in 1Q18. $BDX expects the transaction to generate low-single digit accretion to adjusted EPS in FY18, and high-single digit accretion in FY19.

$BDX {{ '2017-12-29T16:53:59+0000' | timeago}} • Announcement

$BDX completed the acquisition of $BCR. Under the terms of the transaction, Bard became a wholly owned subsidiary of $BDX, and each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of $BDX common stock. Bard shares will cease trading and be delisted from the NYSE.

$BDX {{ '2017-12-28T12:35:48+0000' | timeago}} • Announcement

$BDX gets clearance from the Ministry of Commerce of the People's Republic of China (MOFCOM) to acquire $BCR. BD and Bard expect the proposed acquisition to close on Dec. 29. Separately, BD's proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

Recent Transcripts

CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
CRL (Charles River Laboratories International, Inc.)
Thursday, November 9 2017 - 1:30pm
ELGX (Endologix Inc.)
Tuesday, November 7 2017 - 9:30pm
CUTR (Cutera, Inc.)
Tuesday, November 7 2017 - 9:30pm
CRIS (Curis, Inc.)
Tuesday, November 7 2017 - 1:30pm
CTIC (CTI BioPharma Corp.)
Monday, November 6 2017 - 9:30pm
CYH (Community Health Systems, Inc.)
Thursday, November 2 2017 - 3:00pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
CI (Cigna Corp.)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
CHE (Chemed Corp.)
Friday, October 27 2017 - 2:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
BSX (Boston Scientific Corporation)
Thursday, October 26 2017 - 12:00pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BAX (Baxter International Inc.)
Wednesday, October 25 2017 - 12:30pm
MMM (3M Company)
Tuesday, October 24 2017 - 1:00pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm

AlphaGraphics you may like